Evidence map›Paper›PMID 42640987›Full record

ArticlePLoS biology2026

IP3R2-mediated inter-organelle calcium signaling suppresses melanosome degradation.

Suman Saurav, Anuradha Jadon, Rajender K Motiani

Abstract read
In one paragraph

Article in PLoS biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Suman SauravLaboratory of Calciomics and Systemic Pathophysiology (LCSP), Regional Centre for Biotechnology (RCB), Faridabad, Haryana, India.
Anuradha JadonLaboratory of Calciomics and Systemic Pathophysiology (LCSP), Regional Centre for Biotechnology (RCB), Faridabad, Haryana, India.
Rajender K MotianiLaboratory of Calciomics and Systemic Pathophysiology (LCSP), Regional Centre for Biotechnology (RCB), Faridabad, Haryana, India.ORCID https://orcid.org/0000-0002-8971-9008

Funding

Wellcome Trust
6 · The paper itself

Abstract

Organelle turnover is fundamental to cellular homeostasis and regulates both physiological processes and pathological outcomes. Skin pigmentation is determined by the balance between melanosome biogenesis and degradation. However, the mechanisms governing melanosome degradation, i.e., melanophagy remain largely unappreciated. Here, we reveal Inositol 1,4,5-trisphosphate receptor 2 (IP3R2) as a selective suppressor of melanophagy. To enable real-time monitoring of melanophagy, we developed and characterized two novel ratiometric live-cell imaging probes. Using a multi-pronged strategy combining live-cell imaging with the probes, biochemical studies, ultrastructural analyses, molecular approaches, and calcium imaging, we demonstrate that IP3R2 suppresses melanophagy. Importantly, in vivo studies in zebrafish model and meta-analysis of human skin microarrays substantiate the physiological relevance of IP3R2 in pigmentation. Mechanistically, IP3R2 depletion impairs mitochondrial Ca2+ uptake, elevates the ADP/ATP ratio and initiates melanophagy. Concurrently, IP3R2 loss enhances ER-lysosome contacts, increases lysosomal Ca2+ levels via TMEM165, and activates TRPML1 and nuclear translocation of TFEB. This in turn transcriptionally induces melanophagy receptor and E3 ligase. Collectively, IP3R2 acts as a critical determinant of melanophagy and a potential therapeutic target for pigmentary disorders and skin malignancies.

Indexed as

Calcium SignalingInositol 1,4,5-Trisphosphate ReceptorsMelanosomesAnimalsCalciumEndoplasmic ReticulumHumansLysosomesMelanocytesMitochondriaOrganellesSkin PigmentationZebrafishCalciumInositol 1,4,5-Trisphosphate ReceptorsITPR2 protein, human

Identifiers

PMID42640987
PMCPMC13533435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.